AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. by Cao, Wei et al.
UC Office of the President
Recent Work
Title
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast 
cancer.
Permalink
https://escholarship.org/uc/item/0wb5f5p3
Journal
Breast cancer research : BCR, 21(1)
ISSN
1465-5411
Authors
Cao, Wei
Li, Jieqing
Hao, Qiongyu
et al.
Publication Date
2019-02-21
DOI
10.1186/s13058-019-1107-2
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
REVIEW Open Access
AMP-activated protein kinase: a potential
therapeutic target for triple-negative breast
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Wei Cao1,2, Jieqing Li2,3, Qiongyu Hao2, Jaydutt V Vadgama2* and Yong Wu2*
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subset of breast carcinomas that lack expression of estrogen
receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Unlike other
breast cancer subtypes, targeted therapy is presently unavailable for patients with TNBC. In spite of initial responses
to chemotherapy, drug resistance tends to develop rapidly and the prognosis of metastatic TNBC is poor. Hence,
there is an urgent need for novel-targeted treatment methods or development of safe and effective alternatives
with recognized mechanism(s) of action. AMP-activated protein kinase (AMPK), an energy sensor, can regulate
protein and lipid metabolism responding to alterations in energy supply. In the past 10 years, interest in AMPK has
increased widely since it appeared as an attractive targeting molecule for cancer therapy. There has been a deep
understanding of the possible role of abnormal AMPK signaling pathways in the regulation of growth and survival
and the development of drug resistance in TNBC. The increasing popularity of using AMPK regulators for TNBC-
targeted therapy is supported by a considerable development in ascertaining the molecular pathways implicated.
This review highlights the available evidence for AMPK-targeted anti-TNBC activity of various agents or treatment
strategies, with special attention placed on recent preclinical and clinical advances in the manipulation of AMPK in
TNBC. The elaborative analysis of these AMPK-related signaling pathways will have a noteworthy impact on the
development of AMPK regulators, resulting in efficacious treatments for this lethal disease.
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Background
Breast cancer (BC) is the most common malignant tumor
in women [1]. Approximately 70% of BC patients express
estrogen receptor-α (ERα). Because of the success of endo-
crine therapy, the mortality rate of patients with ERα+ can-
cers has decreased dramatically. Likewise, around 15% of
patients have cancers overexpressing human epidermal
growth factor receptor-2 (HER2) and hence are candidates
for HER2-targeted treatments. Conversely, triple-negative
breast cancer (TNBC) represents cancers lacking clinical
expression of ERα, progesterone receptor (PR), and HER2
(ER-/PR-/HER2-) and cannot be treated with current endo-
crine or HER2-targeted therapies. This type of cancer over-
laps partially with basal-like BC, a subgroup that expresses
specific cytokeratins, and some hereditary BCs. Further-
more, this subtype is associated with undesirable biological
characteristics, such as high mitotic count and aggressive
behavior. While TNBCs only occur in 10–15% of patients,
they account for almost half of all BC deaths. Despite the
heterogeneous nature, TNBCs frequently occur in African
American [2] and younger women [3] and among patients
with BRCA1/2 gene defects [4].
Although the term “TNBC” has only recently appeared
in the medical literature, it has acquired such a degree
of scientific interest that the category of TNBC has now
been fully integrated into the terminology of oncology.
Nowadays, TNBC may be one of the most active fields
in oncology research due to the following reasons: (1) In
the context of the current treatment of BC, there is a
* Correspondence: jayvadgama@cdrewu.edu; yongwu@cdrewu.edu
Jaydutt V Vadgama and Yong Wu are the last authors.
2Division of Cancer Research and Training, Department of Internal Medicine,
Charles R. Drew University of Medicine and Science, David Geffen UCLA
School of Medicine, and UCLA Jonsson Comprehensive Cancer Center, 1748
E. 118th Street, Los Angeles, CA 90059, USA
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cao et al. Breast Cancer Research           (2019) 21:29 
https://doi.org/10.1186/s13058-019-1107-2
lack of accepted molecular therapeutic targets, making
TNBC a new orphan disease; (2) The prognosis of TNBC
patients is comparatively poor, particularly in advanced
patients, making TNBC a very challenging and dishearten-
ing situation for patients and medical oncologists [3]. In
view of the malignancy of TNBC and the mortality rate of
those with metastatic BC, further studies are needed to
improve the prognosis of this subtype of BC.
TNBC treatment
TNBC treatments consist of two parts, namely locoregional
treatments, including surgery and radiotherapy, and sys-
temic treatments, such as chemotherapy and targeted ther-
apy. Compared with locoregional treatments, systemic
treatments are directed toward genetic aberrations and the
molecular status of tumors. The preferred cytotoxic chemo-
therapy regimens for primary TNBC are mainly based on
taxane, anthracycline, and sometimes cyclophosphamide,
while several combination therapies including methotrexate
and epirubicin could be considered [5]. In general, TNBC is
more sensitive to chemotherapy than any other subtype [6],
and pathological complete response (pCR) can be achieved
in 20–30% TNBC cases that received neoadjuvant chemo-
therapy [7]. Although improvements of pCR observed in
TNBC result in prolonged overall survival (OS)/disease-free
survival (DFS) [8], TNBC is still prone to metastasis and re-
currence due to its heterogeneity [9]. For recurrent and
metastatic BC, preferred chemotherapy agents include
doxorubicin, paclitaxel, anti-metabolites (capecitabine and
gemcitabine), and microtubule inhibitors (vinorelbine and
eribulin), while cyclophosphamide, carboplatin, docetaxel,
cisplatin, epirubicin, ixabepilone, and combination therapy
could be treated as additional options [5].
Targeted therapy seems to be a potential solution for
TNBC, and a number of antagonists, inhibitors, activators,
and monoclonal antibodies have been put into preclinical
and clinical trials (reviewed in [10]). The targets of these
new drugs include androgen receptor (AR), poly (ADP-
ribose) polymerase (PARP), cyclin-dependent kinases
(CDKs), checkpoint kinase 1 (CHK1), DNA (cytosine-5)-
methyltransferase 1 (DNMT1), epidermal growth factor
(EGF), EGF receptor (EGFR), fibroblast growth factor re-
ceptor (FGFR), vascular endothelial growth factor (VEGF),
VEGF receptor (VEGFR), p53, PI3K/AKT/mammalian
target of rapamycin (mTOR), SRC, Wee1, and WNT. Up
until now, most of these treatment options have not
achieved satisfactory therapeutic results and olaparib, a
PARP inhibitor, is the only one that has been recom-
mended to treat BRCA1/2-positive recurrent or metastatic
TNBC [5].
AMPK in human TNBC
AMP-activated protein kinase (AMPK), a crucial meta-
bolic sensor that can regulate energy homeostasis at the
cellular and whole body levels, is an important hub be-
tween metabolism and signaling networks. Fifteen years
ago, the tumor suppressor liver kinase B1 (LKB1) was
found to be the main upstream kinase of AMPK, implying
that the tumor suppressor effects of LKB1 may be medi-
ated by AMPK [11]. Since then, AMPK-regulating drugs
have been studied in vitro and in vivo to analyze the role
of AMPK in carcinogenesis and progression of cancer.
Studies examining the potential relationship between
AMPK and its clinicopathologic significance in BC reveal
that the expression levels of AMPK are relatively higher in
TNBC versus non-triple-negative breast cancer (NTNBC)
cell lines and that AMPK is also upregulated in TNBC tis-
sues compared to NTNBC tissues [12]. Expression of
AMPK is correlated with TNM stage, distant metastasis,
and Ki67 status. Patients with positive expression of
AMPK exhibit shorter OS and DFS [12]. These findings
implicate AMPK as a promising prognostic biomarker for
TNBC. Recent evidence has demonstrated that pAMPK is
reduced by approximately 90% in cancer tissues of two co-
horts of 354 primary BC patients versus normal breast
epithelial cells [13]. Moreover, in both cohorts, decreased
AMPK phosphorylation is strikingly related to higher
histological grade and axillary node metastasis. Taken to-
gether, these results demonstrate that AMPK function is
compromised in primary BCs. Decreased AMPK signaling
and the negative correlation with histological grade/axil-
lary node metastasis implicate that AMPK reactivation
has the potential for prevention and treatment in BC.
Given that the molecular pathology of TNBC includ-
ing the pathogenesis of the disease and the resistance
mechanisms to existing therapies is not known, it is
problematic to develop new drugs that effectively target
TNBC. In the past few years, there has been a deep un-
derstanding of the possible role of abnormal AMPK sig-
naling pathways in the regulation of growth and survival
and the development of drug resistance in TNBC.
AMPK activation has positive effects in TNBCs due to
its effect of target inhibition on Akt/mTOR [14]. Fur-
thermore, AMPK activation represses expression of
EGFR, cyclin D1, and cyclin E and phosphorylation of
mitogen-activated protein kinase (MAPK), Src, and sig-
nal transducer and activator of transcription 3 (STAT3)
[15, 16]. These results provide additional information
that is likely to influence the development of TNBC tar-
geted therapy (Fig. 1). Here, we summarize the available
evidence for AMPK-targeted anti-TNBC activity of vari-
ous agents or treatment strategies and attempt to give a
prospect on targeted therapeutic strategies in the future.
Metformin
Metformin is a first-line treatment for type 2 diabetes
mellitus (T2DM) patients. A large number of evidence
supporting that T2DM enhances BC risk [17] makes the
Cao et al. Breast Cancer Research           (2019) 21:29 Page 2 of 10
notion of using metformin as a cancer prevention or
treatment drug a very exciting prospect. Metformin acti-
vates the AMPK pathway by inhibiting complex 1 of the
mitochondrial respiratory chain, resulting in the sup-
pression of mTOR and hence loss of cell proliferation
and repression of glucose synthesis [18]. It is noteworthy
that metformin has been reported to decrease the inci-
dence of cancer [19, 20]. The survival rate of BC patients
treated with metformin is significantly higher than that
of patients without metformin treatment.
As detailed previously, metformin exhibits unique
anti-TNBC actions both in vitro and in vivo [21]. Met-
formin (8–14 mg/day) significantly reduces tumor
growth in the TNBC MDA-MB-231 xenograft mouse
model compared with the untreated control. Moreover,
pretreatment with metformin (8–14mg/day) before in-
jection of MDA-MB-231 cells dramatically reduces
tumor growth and incidence. Indeed, studies have clearly
demonstrated that in terms of apoptosis, TNBC cell lines
are more sensitive to metformin when compared to
non-TNBC cell lines [21]. In view of its anti-TNBC ac-
tivity in vitro and in vivo, metformin should be explored
as a drug for the treatment of this aggressive type of BC.
Nevertheless, there are still many unresolved problems
and contradictory opinions in metformin used for TNBC
treatment. Although metformin has good potential in
vitro for the treatment of TNBC, these reports have not
been substantiated in clinical studies, even though there
is a tendency to decreased distant metastasis [22]. These
contradictory conclusions may be explained by the fol-
lowing reasons: (1) The optimal concentration of met-
formin in laboratory models is higher than the
conventional anti-diabetic dose, which may lead to the
failure of this exposure level in the clinic; (2) Preclinical
models have shown more obvious AMPK phosphoryl-
ation/activation by metformin than the clinical studies.
AICAR
AMPK pharmacologic activator 5-aminoimidazole-4-car-
boxamide ribose (AICAR) is an analog of AMP and ex-
tensively used to stimulate AMPK in experiments. The
mechanism that AICAR activates AMPK is thus different
from that of metformin. AICAR can regulate cellular en-
ergy metabolism and induces mitochondrial proliferation
and apoptosis. It has been demonstrated that AICAR has
anti-cancer effects in many cancers [23–25]. Nevertheless,
the effects of AICAR on BC, especially TNBC, and the
roles of AMPK have been rarely reported.
Fig. 1 Schematic illustration of the AMPK/mTOR signaling pathway in TNBC tumor growth and progression. mTORC1 comprises mTOR, mammalian
lethal with sec-13 protein 8 (mLST8), and regulatory-associated protein of mammalian target of rapamycin (RAPTOR). mTORC1 is activated by growth
factors, nutrients (amino acids), and cellular energy. It stimulates anabolic processes, including protein and nucleotide synthesis via ribosomal protein
S6 kinase (S6K), eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1), and hinders catabolic processes, such as autophagy,
through Unc-51-like kinase 1 (ULK1). mTORC2 consists of mTOR, mLST8, mammalian stress-activated map kinase-interacting protein 1 (mSIN1), and
rapamycin-insensitive companion of mTOR (RICTOR) and is activated by growth factors. mTORC2 activates the AGC kinase family members Akt, serum/
glucocorticoid-regulated kinase (SGK), and protein kinase C (PKC). mTORC1 and mTORC2 are commonly activated in human cancers. AMPK activation
inhibits mTORC1; however, the effect on mTORC2/Akt is not completely clear. Moreover, AMPK activation represses expression of EGFR, cyclin D1, and
cyclin E and phosphorylation of MAPK, Src, and STAT3
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More recently, studies have highlighted the role of
metadherin (MTDH) in stimulating tumor progression,
metastasis, and drug resistance in various cancers. MTDH
is an oncogene that was originally identified as a gene in-
creased in astrocytes treated with TNFα or infected with
HIV1 [26]. MTDH mediates the oncogenic characteristics
of PI3K, Ha-Ras, and c-Myc and influences cell survival
and proliferation by activating Akt [27]. MTDH has also
been reported to induce tumor cell metastasis via activat-
ing NF-κB [28]. A recent study has shown that elevated
MTDH levels are associated with drug resistance through
the induction of multidrug resistance protein 1 (MDR1)
expression in hepatocellular carcinoma (HCC) [29].
MTDH is also involved in tumor angiogenesis [30]. A
study from Gollavilli et al. [31] revealed a new regulatory
mechanism for MTDH expression and demonstrated that
AICAR, by stimulating GSK3β and SIRT1, decreases
MTDH expression via suppressing c-Myc in TNBC cells.
This action of AICAR is related to AMPK activation. Ac-
cordingly, AICAR, via AMPK activation, promotes growth
arrest and anti-proliferative effects and inhibits migration/
invasion of TNBC cells. Taken together, these findings elu-
cidate a novel role of AMPK in regulating oncoproteins.
The use of AMPK activators might substantiate to be
beneficial, at least as an adjuvant therapy combined with
other chemoprevention strategies, where MTDH has been
associated with TNBC progression.
RL71
Autophagy is a conserved catabolism process that de-
livers cytoplasmic constituents and organelles for deg-
radation in the lysosome [32]. It can be triggered by
various stressful conditions, e.g., nutrient deficiency, oxi-
dative stress, and endoplasmic reticulum stress. In fact,
overactivation of autophagy may ultimately cause type II
programmed cell death in tumors [33]. One of the most
important mechanisms of many clinically approved
drugs or experimental small molecules with potential
anti-cancer activity is the ability to induce autophagic
cell death [34]. Induction of autophagic cell death can
provide another way to treat cancer besides inducing
apoptosis. Of note, recent studies have shown that the
expression of autophagy-associated markers LC3/
Beclin-1 in TNBC is the highest among BCs, indicating
a constitutive activation of autophagy in TNBC [35].
Considering the threshold effect of autophagy differenti-
ating survival and death in tumor cells, it is evident that
further promoting autophagy with small molecular in-
ducers can be used as a new TNBC therapy strategy.
More recently, RL71, a second-generation curcumin
analog, has been shown to possess effective anti-cancer
activity on TNBC cells through triggering excessive au-
tophagic cell death [36]. RL71 increases the release of Ca2
+ from the endoplasmic reticulum into the cytosol through
repressing sarco/endoplasmic reticulum calcium-ATPase 2
(SERCA2) activity. Calcium signaling can promote autoph-
agy via multiple mechanisms [37]. Here, The calcium
mobilization induced by RL71 treatment results in the Ca2
+/calmodulin-dependent kinase kinase-β (CaMKKβ)-de-
pendent activation of AMPK, which represses the activity
of the mTOR, a negative regulator of autophagy. Pharma-
ceutical inhibition of either CaMKKβ or AMPK decreases
the conversion of LC3B-I to LC3B-II and inverts
RL71-induced cell death in MDA-MB-468 cells. Accord-
ingly, in TNBC xenograft mouse models, RL71 significantly
inhibits tumor growth, reduces metastasis, and prolongs
survival time. Together, these results indicate that AMPK is
a potential therapeutic target candidate for TNBC and sup-
port the notion that autophagy inducers can be used as
new therapies in TNBC treatment.
Demethoxycurcumin
Recent research has focused on targeting metabolic
pathways that may change during the initiation and de-
velopment of TNBC. The inhibition of cancer cell
growth through activating AMPK has attracted much at-
tention. A study from Shieh et al. [38] investigating the
effects of curcuminoids on the viability of TNBC cells
suggests that demethoxycurcumin (DMC) at low micro-
molar levels potently represses TNBC cell proliferation
by simultaneously inhibiting various oncogenic signaling
pathways and energy metabolism via AMPK activation.
DMC is a structural analog of curcumin, showing
nearly the same biological action as curcumin, e.g., anti-
oxidative, anti-inflammatory, anti-tumor, and anti-angio-
genesis [39] activities. Compared with ER-(+) or
HER2-overexpressing BC cells, DMC exhibits the most
effective cytotoxic effects on TNBC cells. Conversely,
normal human mammary cells are unaffected by DMC
treatment. AMPK was recently demonstrated to inte-
grate growth factor signaling with cellular metabolism
via negatively regulating mTOR [18, 40]. The role of
mTOR is associated with the regulation of mRNA
translation through the eukaryotic initiation factor
4E-binding protein-1 (4E-BP1) in mammalian cells. In
its hyper-phosphorylation form by mTOR, 4E-BP1 even-
tually initiates translation of specific mRNAs, such as
those required for cell cycle progression and those impli-
cated in cell cycle regulation [41]. Indeed, signaling
through DMC-induced AMPK activation is able to block
4E-BP1 signaling and mRNA translation through mTOR
and inhibit the activity/expression of lipogenic enzymes,
e.g., fatty acid synthase (FASN) and acetyl-CoA carb-
oxylase (ACC).
Potential approaches in TNBC treatment include tar-
geting EGFR, which is demonstrated to be crucial for
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the growth and maintenance of TNBC [42]. Of note,
nearly 60% of basal-like TNBC expresses EGFR, and
higher intratumoral expression of EGFR represents a poor
prognosis, indicating EGFR as a molecular target for in-
novative therapeutic inhibitors [42]. Hence, inhibition of
EGFR plays an important role in the phenotypic changes
of TNBC [43]. DMC-mediated AMPK activation pro-
motes EGFR degradation through regulating expression of
the phosphatases, protein phosphatase 2A(PP2A) and
SHP-2, in TNBC cells.
In addition to the aforementioned signaling pathways,
DMC also targets various AMPK downstream targets.
Among these, the dephosphorylation of Akt is notable
since it avoids the feedback activation of Akt induced by
mTOR inhibition. Furthermore, DMC inhibits lipopoly-
saccharides (LPS)-induced IL-6 production, thus hinder-
ing subsequent STAT3 activation. Together, these findings
indicate that DMC is an effective AMPK agonist that acts
through a wide range of anti-TNBC activities, and provide
proof-of-concept that targeting AMPK represents a novel
strategy for TNBC prevention and treatment.
Fluoxetine
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI),
is widely used to regulate serotonin concentration in the
central nervous system [44]. It is also commonly known as
Prozac, which is used to treat depression. Of interest, there
is encouraging evidence to support the contribution of Flu-
oxetine to inhibition of mitochondrial function leading to
autophagic flux and apoptosis [45]. As detailed recently
[46], Fluoxetine has robust anti-proliferative activities and
triggers autophagic cell death in TNBC cells. The mechan-
ism underlying Fluoxetine-induced autophagic cell death is
related to activation of AMPK-mTOR-ULK complex axis
and suppression of eukaryotic elongation factor-2 kinase
(eEF2K). eEF2K, well-known as a Ca2+ calmodulin (CaM)-
dependent kinase, is overexpressed in many cancers,
especially TNBC [47]. Mounting evidence demonstrates
that eEF2K can regulate the expression of various apop-
totic proteins including Bcl-XL, XIAP, c-FLIPL, PI3KCI,
and p70S6K to impede apoptosis in the tumor. Alterna-
tively, eEF2K regulates autophagy implicated in AMPK,
mTORC1, and ULK1, thus promoting tumor cell survival
[48]. In addition, eEF2K may play an important role in the
crosstalk between autophagic and apoptotic processes in
TNBC.
In summary, these findings suggest that Fluoxetine ef-
fectively inhibits tumor growth of TNBC via promoting
apoptosis and autophagy associated with suppression of
eEF2K and activation of the AMPK-mTOR-ULK signaling
pathway. These results have also led to the conclusion that
AMPK may be a novel anti-TNBC target, and activating
AMPK/inhibiting eEF2K will be a promising therapeutic
strategy for TNBC.
miR-200a
MicroRNA (miRNA) replacement therapy represents a
promising way to target cancer pathways. miRNAs are
small non-coding RNAs that have the ability to act as can-
cer suppressors and are commonly lost in several cancers
[49]. Since miRNAs typically target various genes and
pathways concurrently, an important benefit of miRNA
replacement therapy is a lower resistance. The miR-200
family (miR-200a, -200b, -200c, -141, -429) is emerging as
important cancer suppressor miRNAs [50]. Decreased ex-
pression of the miR-200 family is observed in TNBC and
correlated with epithelial-to-mesenchymal transition
(EMT), cancer progression, and an aggressive cancer
phenotype [51]. miR-200a impedes EMT through target-
ing the E-cadherin suppressors ZEB1/2 or SUZ12, leading
to augmented levels of E-cadherin [52]. Since the reduc-
tion of E-cadherin expression is a feature of the TNBC
subgroup [53] and these miRNAs are reduced in TNBC
cells, miR-200 replacement therapy is an interesting op-
tion for future TNBC therapy.
More recently, miR-200a has been shown to reduce
cell migration of TNBC, through its downregulation of
the oncogene EPH receptor A2 (EPHA2) and subsequent
activation of AMPK [54]. EPHA2 binds ephrin-A ligands
on the cell membrane and modulates cell–cell inter-
action. Ephrin-A1-EPHA2 binding leads to receptor deg-
radation and inhibition of migration and proliferation,
while EPHA2 accumulates and induces invasiveness in
the absence of ligand [55]. Multiple clinical data indicate
a tumorigenic role for EPHA2 in BC development [56].
Of note, EPHA2 is overexpressed in TNBC cells whereas
the ligand Ephrin-A1 is undetectable; hence, EPHA2
plays an important role in promoting TNBC invasion
[57]. Thus, EPHA2 has been considered as a promising
therapeutic target for TNBC. Actually, the expression of
EPHA2 is associated with the poor survival rate of basal-
like BC and that its expression is inhibited by miR-200a by
directly interacting with the 3′UTR of EPHA2 [54]. There-
fore, it is evident that the miR-200a-EPHA2-AMPK axis is
a new mechanism highlighting the significance of utilizing
AMPK activation to target TNBC metastases.
OSU-53
Lee et al. developed a lead AMPK-activating compound
OSU-53 by using ciglitazone as a scaffold on the basis of
the finding that thiazolidinediones induce AMPK activa-
tion partially through a peroxisome proliferator-activated
receptor (PPAR)γ-independent mechanism [58]. OSU-53
is a PPARγ-inactive derivative, which stimulates the activ-
ity of AMPK kinase by efficient direct activation. This
mechanism is different from that of metformin or AICAR.
OSU-53 potently inhibits TNBC by simultaneously
hindering various oncogenic signaling pathways and en-
ergy metabolism as a result of AMPK activation [58].
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Among those, the PP2A-dependent dephosphorylation
of Akt is important since it avoids the feedback activa-
tion of Akt caused by mTOR inhibition. OSU-53 also
regulates energy homeostasis by inhibiting fatty acid
(FA) biosynthesis and shifting the metabolism to oxida-
tion through increasing the expression of primary regu-
latory factors of mitochondrial biogenesis, including
PPARγ coactivator 1α (PGC-1α) and the transcription
factor nuclear respiratory factor 1. Additionally, OSU-53
inhibits LPS-induced IL-6 production, thus hindering
subsequent activation of STAT3. It is also noteworthy
that OSU-53 suppresses hypoxia-induced EMT through
decreasing the expression of hypoxia-inducible factor
1-alpha (HIF1α) and the E-cadherin repressor Snail. In
spite of its extensive anti-cancer activities, OSU-53 does
not significantly affect non-malignant MCF-10A cells,
partially owing to the low basal activation levels of Akt/
mTOR. Importantly, oral OSU-53 inhibits TNBC xeno-
graft tumor growth without overt toxicity. This in vivo
efficacy, together with the wide range of anti-cancer
properties of OSU-53, provides proof-of-concept that
AMPK is an important therapeutic target for TNBC.
In addition to the AMPK activators mentioned above,
polyphenols have also been shown to inhibit TNBC by
activating AMPK. A combined diet of grape polyphenols
comprising of resveratrol, quercetin, and catechin (RQC)
impedes TNBC growth and metastasis in nude mice.
Furthermore, RQC sensitizes TNBC tumors to the
anti-EGFR therapeutic gefitinib, through activation of
AMPK and subsequent suppression of the Akt/mTOR
pathway [59]. Of note, this study further substantiated
the relative contribution of AMPK activation to the ef-
fects of RQC on mTOR pathway, concomitant with a
decrease in the TNBC progression, which is further tes-
tament to the significance of targeting AMPK in the
TNBC therapy.
AMPK inhibition in TNBC treatment
AMPK activation in response to stress is associated with
augmented resistance to death in many cellular systems.
Thus, the effects of AMPK activation in cancer seem
much more complicated than originally thought, and
AMPK can act as a cancer “friend” or “enemy” in spe-
cific circumstances. AMPK supra-physiological activa-
tion induced by drugs decreases cancer growth in vitro
and in preclinical models by inhibiting crucial biosyn-
thetic pathways [60, 61]. Nevertheless, AMPK’s physio-
logical activation upon various stresses, such as hypoxia
and glucose deprivation, provides metabolic adaptation
for tumor cells to survive metabolic stress [62]. Upon
glucose depletion, AMPK is activated and harmoniously
supports cell survival through multiple mechanisms in-
cluding (1) induction of autophagy [63], (2) promotion
of fatty acid oxidation to produce ATP [64, 65], (3)
transcriptional alterations induced by the core histone
H2B phosphorylation [66], and (4) elevation of intracel-
lular NADPH levels to combat cytotoxic ROS [67].
Therefore, although the LKB1/AMPK pathway can be
considered as a tumor suppressor, it can also act as a
“tumor-promoting factor,” making cancer cells more re-
sistant to metabolic stress. In view of the complex roles
of AMPK under different metabolic conditions, the role
of AMPK in cancer should be reconsidered carefully.
In our own laboratory, we demonstrated that DNA
damage (UV or bleomycin), via PARP-1 activation, in-
duces ATP depletion at earlier times, which results in
AMPK activation and ATP increase at later times of DNA
damage. Treating cancer cells with the AMPK inhibitor,
compound C, or overexpression of a dominant-negative
mutant of AMPK (DN-AMPK) blocked elevation of ATP
levels at later times of DNA damage, causing significant
cell apoptosis [68]. More recently, our findings [69] indi-
cated that 2-deoxyglucose (2-DG), a glycolytic inhibitor,
activates AMPK, followed by a partial restore of intracel-
lular ATP levels. Thus, the inhibitory effect of 2-DG on
cancer cell growth is partially offset by the fact that there
is also 2-DG-induced AMPK activation. Of note, com-
pound C, an AMPK inhibitor, synergistically reinforced
the inhibitory effect of 2-DG on ATP production and
caused a dramatic increase in cytotoxicity in breast cancer
cells but not in normal MCF-10A cells. The killing effect
of this 2-DG/compound C combination treatment on
TNBC cells is more obvious than on MCF-7. Together, we
demonstrate that combination treatment of DNA dam-
aging therapeutic agents or 2-DG and AMPK inhibitors is
a potentially promising, safe, and effective breast cancer
treatment strategy.
In short, these evidently contradictory results indicate
that both AMPK agonists and antagonists may provide
therapeutic benefits in distinct cancer types, genetic/
metabolic circumstances, and micro-environmental con-
ditions. Therefore, the choice of AMPK regulators might
be different at different stages of carcinogenesis or can-
cer progression, or in different treatment contexts.
Translational challenges
TNBCs are predominantly sensitive to blockade of the
mTOR pathway. The mTOR signal passes through two
multi-protein complexes, i.e., mTORC1 and mTORC2
(Fig. 1). A study [14] using RNA interference experi-
ments to determine the contribution of each of the two
complexes to the modulation of TNBC cell number sug-
gests that mTORC1 is superior to mTORC2 in control-
ling TNBC cell proliferation. Additionally, the RNA
interference of mTOR has a better anti-proliferative ef-
fect than that of mTOR1 or mTOR2 alone. Thus,
mTOR targeting could be a more effective anti-TNBC
treatment versus solely acting on the mTORC1 pathway.
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This is relevant as the majority of mTOR inhibitors used
in the clinic functions on mTORC1.
Although targeting AMPK/mTOR has become a po-
tential target for cancer treatment, in some cases, AMPK
activation might promote cancer. A majority of tumors
have activation in mTORC1, which promotes growth
through effectors including 4E-BP1 and S6K1, as men-
tioned above. Therefore, inhibition of mTORC1 will
thwart cell protein synthesis and proliferation; nonethe-
less, as mentioned earlier, the inhibition of mTORC1
without impeding mTORC2 may result in compensatory
stimulation of PI3K/Akt signaling pathway and promo-
tion of cancer survival. In most cases, AMPK activation
leads to mTORC1 repression; but the effects on
mTORC2/Akt activation are not entirely clear. If a spe-
cific AMPK activator is only used to modulate mTOR,
its success will depend on its ability to inhibit the two
mTOR branches. AMPK agonists have the ability to in-
hibit or promote tumors, which may be due to
feedback-related mechanisms under specific circum-
stances. Therefore, the biggest translational challenge of
exploiting AMPK as a therapeutic target and developing
AMPK agonists is how to promote the anti-cancer effect
and circumvent pro-cancer effects.
Conclusions
Substantial evidence supports the idea that AMPK acti-
vation may be used as a metabolic cancer suppressor.
We can presume that AMPK activation may counteract
the development of cancer through reprogramming cel-
lular metabolism and targeting one of the essential com-
ponents necessary for tumor progression. In fact, AMPK
function is compromised in primary BCs and loss of
AMPK signaling is related to a worse clinical outcome,
implicating that AMPK reactivation has the potential for
prevention and treatment in BC. Recently, the possible
role of an abnormal AMPK signaling pathway in the
growth, survival, and drug resistance of TNBC has been
well understood. Of pertinence to this review, various
AMPK agonists such as metformin, AICAR, RL71,
DMC, Fluoxetine, miR-200a, and OSU-53 were demon-
strated to significantly inhibit TNBC. Activation of
AMPK has positive effects in TNBCs because of its tar-
geting inhibition effect on Akt/mTOR. Additionally,
AMPK activation suppresses EGFR, c-Myc, IL6, Jak/
STAT3, HIF-1α, and eEF2K, which are well-established
hallmarks of TNBCs. On the other hand, under certain
circumstances, such as in combination with DNA dam-
aging therapeutic agents or glycolytic inhibitors, inhib-
ition of AMPK can also be used as a means to treat
TNBC. Therefore, it is plausible to consider AMPK as
an attractive therapeutic target for TNBC (Fig. 2).
Future preclinical and clinical studies would have to
further substantiate the anti-TNBC effects of AMPK ac-
tivation by using more specific, direct, and potent
AMPK activators. In addition, all other indirect effects
Fig. 2 Proposed molecular action of AMPK activation by various classical/novel AMPK activators in TNBC. Abbreviations: DMC, demethoxycurcumin;
AICAR, 5-aminoimidazole-4-carboxamide ribose; SERCA2, sarco/endoplasmic reticulum calcium-ATPase 2; CaMKKβ, Ca2+/calmodulin-dependent kinase
kinase-β; RC: respiratory chain; EPHA2, EPH receptor A2; MTDH, metadherin
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of AMPK activation remain to be studied. Hence, add-
itional studies are needed before AMPK activators can
be used for clinical treatment of TNBC. At the time of
writing this review, more than 100 patents have been
filed for new small molecule AMPK agonists, and it is
hoped that some of them will soon enter clinical trials.
It seems possible that within 5–10 years, we will know
more clearly whether a more selective and potent AMPK
activator than metformin will have a place in the treat-
ment of TNBCs.
Abbreviations
4E-BP1: eIF4E-Binding protein-1; ACC: Acetyl-CoA carboxylase; AICAR:
5-Aminoimidazole-4-carboxamide ribose; AMPK: AMP-activated protein
kinase; AR: Androgen receptor; BC: Breast cancer; CaMKKβ: Ca2+/calmodulin-
dependent kinase kinase-β; DFS: Disease-free survival;
DMC: Demethoxycurcumin; eEF2K: Eukaryotic elongation factor-2 kinase;
EGFR: Epidermal growth factor receptor; EMT: Epithelial-to-mesenchymal
transition; EPHA2: EPH receptor A2; ER: Estrogen receptor; FA: Fatty acid;
FASN: Fatty acid synthase; HCC: Hepatocellular carcinoma; HER2: Human
epidermal growth factor receptor-2; HIF1α: Hypoxia-inducible factor 1-alpha;
LKB1: Liver kinase B1; MAPK: Mitogen-activated protein kinase;
miRNA: MicroRNA; MTDH: Metadherin; mTOR: Mammalian target of
rapamycin; NTNBC: Non-triple-negative breast cancer; OS: Overall survival;
PARP: Poly [ADP-ribose] polymerase; PGC-1α: PPARγ coactivator 1α;
PKC: Protein kinase C; PP2A: Protein phosphatase 2A; PPAR: Peroxisome
proliferator-activated receptor; PR: Progesterone receptor;
RAPTOR: Regulatory-associated protein of mammalian target of rapamycin;
RICTOR: Rapamycin-insensitive companion of mTOR; RQC: Resveratrol,
quercetin, and catechin; SERCA2: Sarco/endoplasmic reticulum calcium-
ATPase 2; SGK: Serum/glucocorticoid-regulated kinase; SSRI: Selective
serotonin reuptake inhibitor; STAT3: Signal transducer and activator of
transcription 3; T2DM: Type 2 diabetes mellitus; TNBC: Triple-negative breast
cancer; VEGFR: Vascular endothelial growth factor receptor
Acknowledgements
We wish to thank Ms. Man Yee Keung (Charles Drew University) for
assistance in editing this manuscript.
Funding
This work was supported in part by NIH-NIMHD U54MD007598, NIH/NCI1
U54CA14393, U56CA101599-01; Department-of-Defense Breast Cancer Research
Program grant BC043180, NIH/NCATS CTSI UL1TR000124 to J.V. Vadgama, and
Accelerating Excellence in Translational Science Pilot Grants G0812D05, NIH/NCI
SC1CA200517 to Y. Wu.; The National Natural Science Foundation of China
81630049; National Key R&D Program of China 2017YFC0113302; China
Scholarship Council 201706165022.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or
analysed during the current study
Authors’ contributions
WC performed the literature search, wrote and edited the manuscript, and
generated the figures. JL and QH wrote and edited the manuscript. JV and
YW conceptualized the paper, wrote and edited the manuscript, generated
the figures, and provided overall supervision and co-ordination of the manuscript
preparation. All authors were involved in writing the manuscript and approved
the submitted final version of the manuscript.
Ethics approval and consent to participate
Not applicable
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College,
Huazhong University of Science and Technology, Wuhan 430022, China.
2Division of Cancer Research and Training, Department of Internal Medicine,
Charles R. Drew University of Medicine and Science, David Geffen UCLA
School of Medicine, and UCLA Jonsson Comprehensive Cancer Center, 1748
E. 118th Street, Los Angeles, CA 90059, USA. 3Department of Breast Surgery,
Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China.
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide
for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A.
Breast cancer statistics, 2015: convergence of incidence rates between black
and white women. CA Cancer J Clin. 2016;66(1):31–42.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA,
Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features
and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.
4. Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos
MC, Gallardo L, Alvarez-Gomez RM, Herzog J, Castillo D, Royer R, et al. The
prevalence of BRCA1 and BRCA2 mutations among young Mexican women
with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(2):389–94.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines
in Oncology:Breast Cancer(Version 4. 2018) https://www.nccn.org/
professionals/physician_gls/pdf/breast.pdf. Accessed 8 Feb.
6. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF,
Gonzalez-Angulo AM, Hennessy B, Green M, et al. Response to neoadjuvant
therapy and long-term survival in patients with triple-negative breast
cancer. J Clin Oncol. 2008;26(8):1275–81.
7. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA,
Gerber B, Eiermann W, Hilfrich J, Huober J, et al. Definition and impact of
pathologic complete response on prognosis after neoadjuvant
chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;
30(15):1796–804.
8. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi
H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response
and long-term clinical benefit in breast cancer: the CTNeoBC pooled
analysis. Lancet. 2014;384(9938):164–72.
9. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-
Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al.
Differential response to neoadjuvant chemotherapy among 7 triple-negative
breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–40.
10. Jhan JR, Andrechek ER. Triple-negative breast cancer and the potential for
targeted therapy. Pharmacogenomics. 2017;18(17):1595–609.
11. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA,
Cantley LC. The tumor suppressor LKB1 kinase directly activates AMP-
activated kinase and regulates apoptosis in response to energy stress. Proc
Natl Acad Sci U S A. 2004;101(10):3329–35.
12. Huang X, Li X, Xie X, Ye F, Chen B, Song C, Tang H, Xie X. High expressions
of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast. 2016;
30:39–46.
13. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock
D, Jordan LB, Purdie CA, Hardie DG, et al. Histological evaluation of AMPK
signalling in primary breast cancer. BMC Cancer. 2009;9:307.
14. Montero JC, Esparis-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R,
Ocana A, Pandiella A. Active kinase profiling, genetic and pharmacological
data define mTOR as an important common target in triple-negative breast
cancer. Oncogene. 2014;33(2):148–56.
15. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R,
Thor AD. Metformin targets Stat3 to inhibit cell growth and induce
apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11(2):367–76.
Cao et al. Breast Cancer Research           (2019) 21:29 Page 8 of 10
16. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA,
Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, et al. Evaluation of
metformin in early breast cancer: a modification of the traditional paradigm
for clinical testing of anti-cancer agents. Breast Cancer Res Treat. 2011;
126(1):215–20.
17. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP. Type 2 diabetes and
cancer: umbrella review of meta-analyses of observational studies. BMJ.
2015;350:g7607.
18. Zordoky BN, Bark D, Soltys CL, Sung MM, Dyck JR. The anti-proliferative
effect of metformin in triple-negative MDA-MB-231 breast cancer cells is
highly dependent on glucose concentration: implications for cancer therapy
and prevention. Biochim Biophys Acta. 2014;1840(6):1943–57.
19. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin
and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5.
20. Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G, Schunemann HJ,
Muti P. Association of Metformin with breast cancer incidence and mortality in
patients with type II diabetes: a GRADE-assessed systematic review and meta-
analysis. Cancer Epidemiol Biomark Prev. 2018;27(6):627–35.
21. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD.
Metformin induces unique biological and molecular responses in triple
negative breast cancer cells. Cell Cycle. 2009;8(13):2031–40.
22. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L,
Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival
outcomes in diabetic patients with triple receptor-negative breast cancer.
Cancer. 2012;118(5):1202–11.
23. Morishita M, Kawamoto T, Hara H, Onishi Y, Ueha T, Minoda M, Katayama E,
Takemori T, Fukase N, Kurosaka M, et al. AICAR induces mitochondrial
apoptosis in human osteosarcoma cells through an AMPK-dependent
pathway. Int J Oncol. 2017;50(1):23–30.
24. Dolinar K, Jan V, Pavlin M, Chibalin AV, Pirkmajer S. Nucleosides block
AICAR-stimulated activation of AMPK in skeletal muscle and cancer cells.
Am J Physiol Cell Physiol. 2018;315(6):C803–C817.
25. Lee KC, Lin CT, Chang SF, Chen CN, Liu JL, Huang WS. Effect of AICAR and
5-fluorouracil on X-ray repair, cross-complementing group 1 expression, and
consequent cytotoxicity regulation in human HCT-116 colorectal cancer
cells. Int J Mol Sci. 2017;18(11):2363.
26. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB. Cloning and
characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene.
2005;353(1):8–15.
27. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF,
Pookot D, Majid S, Igawa M, et al. Knockdown of astrocyte-elevated gene-1
inhibits prostate cancer progression through upregulation of FOXO3a
activity. Oncogene. 2007;26(55):7647–55.
28. Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, Fisher PB. Molecular basis of
nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res.
2008;68(5):1478–84.
29. Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills
AS, Waxman S, Fisher RA, Llovet JM, et al. Astrocyte elevated gene-1
regulates hepatocellular carcinoma development and progression. J Clin
Invest. 2009;119(3):465–77.
30. Emdad L, Lee SG, Su ZZ, Jeon HY, Boukerche H, Sarkar D, Fisher PB.
Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates
angiogenesis. Proc Natl Acad Sci U S A. 2009;106(50):21300–5.
31. Gollavilli PN, Kanugula AK, Koyyada R, Karnewar S, Neeli PK, Kotamraju S.
AMPK inhibits MTDH expression via GSK3beta and SIRT1 activation:
potential role in triple negative breast cancer cell proliferation. FEBS J. 2015;
282(20):3971–85.
32. Scarlatti F, Granata R, Meijer AJ, Codogno P. Does autophagy have a license
to kill mammalian cells? Cell Death Differ. 2009;16(1):12–20.
33. White E. Deconvoluting the context-dependent role for autophagy in
cancer. Nat Rev Cancer. 2012;12(6):401–10.
34. Cerezo M, Lehraiki A, Millet A, Rouaud F, Plaisant M, Jaune E, Botton T, Ronco C,
Abbe P, Amdouni H, et al. Compounds triggering ER stress exert anti-melanoma
effects and overcome BRAF inhibitor resistance. Cancer Cell. 2016;30(1):183.
35. Choi J, Jung W, Koo JS. Expression of autophagy-related markers beclin-1,
light chain 3A, light chain 3B and p62 according to the molecular subtype
of breast cancer. Histopathology. 2013;62(2):275–86.
36. Gao J, Fan M, Peng S, Zhang M, Xiang G, Li X, Guo W, Sun Y, Wu X, Wu X,
et al. Small-molecule RL71-triggered excessive autophagic cell death as a
potential therapeutic strategy in triple-negative breast cancer. Cell Death
Dis. 2017;8(9):e3049.
37. Harr MW, Distelhorst CW. Apoptosis and autophagy: decoding calcium
signals that mediate life or death. Cold Spring Harb Perspect Biol. 2010;
2(10):a005579.
38. Shieh JM, Chen YC, Lin YC, Lin JN, Chen WC, Chen YY, Ho CT, Way TD.
Demethoxycurcumin inhibits energy metabolic and oncogenic signaling
pathways through AMPK activation in triple-negative breast cancer cells. J
Agric Food Chem. 2013;61(26):6366–75.
39. Suzuki M, Nakamura T, Iyoki S, Fujiwara A, Watanabe Y, Mohri K, Isobe K,
Ono K, Yano S. Elucidation of anti-allergic activities of curcumin-related
compounds with a special reference to their anti-oxidative activities. Biol
Pharm Bull. 2005;28(8):1438–43.
40. Xu J, Ji J, Yan XH. Cross-talk between AMPK and mTOR in regulating energy
balance. Crit Rev Food Sci Nutr. 2012;52(5):373–81.
41. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth
control in tumour suppression. Nat Rev Cancer. 2009;9(8):563–75.
42. Sutton LM, Han JS, Molberg KH, Sarode VR, Cao D, Rakheja D, Sailors J, Peng
Y. Intratumoral expression level of epidermal growth factor receptor and
cytokeratin 5/6 is significantly associated with nodal and distant metastases
in patients with basal-like triple-negative breast carcinoma. Am J Clin
Pathol. 2010;134(5):782–7.
43. Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, Lavi S,
Lindzen M, Ben-Chetrit N, Sela M, et al. Inhibition of triple-negative breast
cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U
S A. 2013;110(5):1815–20.
44. Caiaffo V, Oliveira BD, de Sa FB, Evencio Neto J. Anti-inflammatory,
antiapoptotic, and antioxidant activity of fluoxetine. Pharmacol Res Perspect.
2016;4(3):e00231.
45. de Oliveira MR. Fluoxetine and the mitochondria: a review of the
toxicological aspects. Toxicol Lett. 2016;258:185–91.
46. Sun D, Zhu L, Zhao Y, Jiang Y, Chen L, Yu Y, Ouyang L. Fluoxetine induces
autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple
negative breast cancer. Cell Prolif. 2018;51(2):e12402.
47. Fu LL, Xie T, Zhang SY, Liu B. Eukaryotic elongation factor-2 kinase (eEF2K): a
potential therapeutic target in cancer. Apoptosis. 2014;19(10):1527–31.
48. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646–74.
49. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and
tumor suppressors. Dev Biol. 2007;302(1):1–12.
50. Feng X, Wang Z, Fillmore R, Xi Y. MiR-200, a new star miRNA in human
cancer. Cancer Lett. 2014;344(2):166–73.
51. Piasecka D, Braun M, Kordek R, Sadej R, Romanska H. MicroRNAs in regulation
of triple-negative breast cancer progression. J Cancer Res Clin Oncol. 2018.
52. Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K.
Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression
required for the formation and maintenance of cancer stem cells. Mol Cell.
2010;39(5):761–72.
53. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H, Ishikawa
T, Wakasa K, Hirakawa K. Significance of E-cadherin expression in triple-
negative breast cancer. Br J Cancer. 2010;103(2):249–55.
54. Tsouko E, Wang J, Frigo DE, Aydogdu E, Williams C. miR-200a inhibits
migration of triple-negative breast cancer cells through direct repression of
the EPHA2 oncogene. Carcinogenesis. 2015;36(9):1051–60.
55. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J,
Wu J, Danielpour D, et al. EphA2 mediates ligand-dependent inhibition and
ligand-independent promotion of cell migration and invasion via a
reciprocal regulatory loop with Akt. Cancer Cell. 2009;16(1):9–20.
56. Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen
J. Eph/ephrin profiling in human breast cancer reveals significant associations
between expression level and clinical outcome. PLoS One. 2011;6(9):e24426.
57. Vaught D, Brantley-Sieders DM, Chen J. Eph receptors in breast cancer: roles in
tumor promotion and tumor suppression. Breast Cancer Res. 2008;10(6):217.
58. Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, Shapiro CL, Chen CS.
Targeting energy metabolic and oncogenic signaling pathways in triple-
negative breast cancer by a novel adenosine monophosphate-activated
protein kinase (AMPK) activator. J Biol Chem. 2011;286(45):39247–58.
59. Rivera-Rivera A, Castillo-Pichardo L, Dharmawardhane SF. Regulation of Akt/
AMPK/mTOR signaling by grape polyphenols in triple negative breast
cancer. FASEB J. 2013;27(1_supplement):607.601-607.601.
60. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a
target in metabolic disorders and cancer. Biochim Biophys Acta. 2010;
1804(3):581–91.
Cao et al. Breast Cancer Research           (2019) 21:29 Page 9 of 10
61. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell
growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–23.
62. Liang J, Mills GB. AMPK: a contextual oncogene or tumor suppressor?
Cancer Res. 2013;73(10):2929–35.
63. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W,
Vasquez DS, Joshi A, Gwinn DM, Taylor R, et al. Phosphorylation of ULK1
(hATG1) by AMP-activated protein kinase connects energy sensing to
mitophagy. Science. 2011;331(6016):456–61.
64. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the
AMP-activated protein kinase. Biochem Soc Trans. 2002;30(Pt 6):1064–70.
65. Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, Huang P, Sawyer SK,
Fuerth B, Faubert B, et al. Carnitine palmitoyltransferase 1C promotes cell
survival and tumor growth under conditions of metabolic stress. Genes Dev.
2011;25(10):1041–51.
66. Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B, Carling D,
Thompson CB, Jones RG, Berger SL. Signaling kinase AMPK activates stress-
promoted transcription via histone H2B phosphorylation. Science. 2010;
329(5996):1201–5.
67. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote
tumour cell survival during energy stress. Nature. 2012;485(7400):661–5.
68. Wu Y, Lin JC, Piluso LG, Dhahbi JM, Bobadilla S, Spindler SR, Liu X.
Phosphorylation of p53 by TAF1 inactivates p53-dependent transcription in
the DNA damage response. Mol Cell. 2014;53(1):63–74.
69. Wu Y, Sarkissyan M, McGhee E, Lee S, Vadgama JV. Combined inhibition of
glycolysis and AMPK induces synergistic breast cancer cell killing. Breast
Cancer Res Treat. 2015;151(3):529–39.
Cao et al. Breast Cancer Research           (2019) 21:29 Page 10 of 10
